Pfizer Statement on today’s joint meeting of FDA Advisory Committees

12-02-2014 Business Wire HealthComments (0)


Pfizer agrees with the recommendation of the joint meeting of the FDA Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee that the available data do not support a conclusion that naproxen has a lower risk of cardiovascular thrombotic events as compared to other non-steroidal anti-inflammatory drugs (NSAIDs). Based on Pfizer’s review of the data discussed, we believe there is insufficient evidence to make this type of distinction. Differ

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top